Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Sep 20;9(9):e030596.
doi: 10.1136/bmjopen-2019-030596.

Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis

Kathryn S Taylor  1 , Julie Mclellan  2 , Jan Y Verbakel  1   3 , Jeffrey K Aronson  1 , Daniel S Lasserson  1   4 , Nicola Pidduck  1 , Nia Roberts  5 , Susannah Fleming  1 , Christopher A O'Callaghan  6 , Clare R Bankhead  1 , Amitava Banerjee  7 , Fd Richard Hobbs  1 , Rafael Perera  1
Affiliations
Meta-Analysis

Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis

Kathryn S Taylor et al. BMJ Open. .

Abstract

Objective: To evaluate the effects of drug interventions that may modify the progression of chronic kidney disease (CKD) in adults with CKD stages 3 and 4.

Design: Systematic review and meta-analysis.

Methods: Searching MEDLINE, EMBASE, Database of Abstracts of Reviews of Effects, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, International Clinical Trials Registry Platform, Health Technology Assessment, Science Citation Index, Social Sciences Citation Index, Conference Proceedings Citation Index and Clinical Trials Register, from March 1999 to July 2018, we identified randomised controlled trials (RCTs) of drugs for hypertension, lipid modification, glycaemic control and sodium bicarbonate, compared with placebo, no drug or a drug from another class, in ≥40 adults with CKD stages 3 and/or 4, with at least 2 years of follow-up and reporting renal function (primary outcome), proteinuria, adverse events, maintenance dialysis, transplantation, cardiovascular events, cardiovascular mortality or all-cause mortality. Two reviewers independently screened citations and extracted data. For continuous outcomes, we used the ratio of means (ROM) at the end of the trial in random-effects meta-analyses. We assessed methodological quality with the Cochrane Risk of Bias Tool and confidence in the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.

Results: We included 35 RCTs and over 51 000 patients. Data were limited, and heterogeneity varied. Final renal function (estimated glomerular filtration rate) was 6% higher in those taking glycaemic control drugs (ROM 1.06, 95% CI 1.02 to 1.10, I2=0%, low GRADE confidence) and 4% higher in those taking lipid-modifying drugs (ROM 1.04, 95% CI 1.00 to 1.08, I2=88%, very low GRADE confidence). For RCTs of antihypertensive drugs, there were no significant differences in renal function. Treatment with lipid-modifying drugs led to a 36% reduction in cardiovascular disease and 26% reduction in all-cause mortality.

Conclusions: Glycaemic control and lipid-modifying drugs may slow the progression of CKD, but we found no pooled evidence of benefit nor harm from antihypertensive drugs. However, given the data limitations, further research is needed to confirm these findings.

Prospero registration number: CRD42015017501.

Keywords: Cardiovascular events; Chronic renal failure; Drug treatment; Meta-analysis; Renal function.

PubMed Disclaimer

Conflict of interest statement

Competing interests: KST, JM, JKA and SF receive funding from the NIHR Programme for Applied Research. JYV receives funding from the NIHR Community Healthcare MIC, Nuffield Department of Primary Care Health Sciences and University of Oxford NIHR Diagnostic Evidence Co-operative (DEC). DSL receives funding from the NIHR Community Healthcare MIC. FDRH acknowledges his part-funding from the National Institute for Health Research (NIHR) School for Primary Care Research, the NIHR Collaboration for Leadership in Health Research and Care (CLAHRC) Oxford, the NIHR Oxford Biomedical Research Centre (BRC) (UHT), and the NIHR Oxford Medtech and In Vitro Diagnostics Co-operative (MIC). RP receives funding from the NIHR Oxford Biomedical Research Centre Programme, the NIHR Programme for Applied Research, the NIHR HPRU Gastrointestinal Infections Group, and the NIHR Diagnostic Evidence Co-operative (DEC).

Figures

Figure 1
Figure 1
PRISMA diagram. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. CKD, chronic kidney disease; MDRD, Modification of Diet in Renal Disease.
Figure 2
Figure 2
ROM of estimated glomerular filtration rate at the end of the trials for antihypertensives versus comparator (boxes) and pooled estimates across studies (diamonds) calculated by the random-effects DerSimonian and Laird method, split by CKD stage. CHARMa and CHARMb, CKD stages 3 and 4, respectively, with estimated glomerular filtration rate measured by the MDRD equation. IDNTa, intervention is irbesartan; IDNTb, intervention is amlodipine. CKD, chronic kidney disease; MDRD, Modification of Diet in Renal Disease; ROM, ratio of means.
Figure 3
Figure 3
ROM of estimated glomerular filtration rate at the end of the trials for lipid-modifying drugs versus comparator (boxes) and pooled estimates across studies (diamonds) calculated by the random-effects DerSimonian and Laird method, split by CKD stage. ASCOT-LLAa, atorvastatin and amlodipine versus placebo and amlodipine; ASCOT-LLAb, atorvastatin and atenolol versus placebo and atenolol; GISSI-HFa, CKD stage 3; GISSI-HFb, CKD stage 4; GREACEa, atorvastatin versus usual care for the group with metabolic syndrome; GREACEb, atorvastatin versus usual care for the group without metabolic syndrome; SHARPa, CKD stages 1–3; SHARPb, CKD stage 4. CKD, chronic kidney disease; ROM, ratio of means; SHARP, Study of Heart and Renal Protection.
Figure 4
Figure 4
ROM of estimated glomerular filtration rate at the end of the trials for glycaemic control drugs versus comparator (boxes) and pooled estimates across studies (diamonds) calculated by the random-effects DerSimonian and Laird method, split by CKD stage. Bode 2015L, intervention is low-dose canagliflozin (100 mg per day); Bode 2015H, intervention is high-dose canagliflozin (300 mg per day); EMPA-REG H, intervention is high-dose empagliflozin (25 mg daily); EMPA-REG L, intervention is low-dose empagliflozin (10 mg daily); Kohan 2014L, intervention is low-dose dapagliflozin (5 mg per day); Kohan 2014H, intervention is high-dose dapagliflozin (10 mg per day); CANVASa, CKD stage 3a; CANVASb, CKD stage 3b; TECOSa, CKD stage 3a; TECOSb, CKD stage 3b. CKD, chronic kidney disease; ROM, ratio of means.
Figure 5
Figure 5
Effect of treatment on estimated glomerular filtration rate by drug class: CKD stages 3 and 4 only. ROM >1 favoured the intervention group (higher values are better). ‘Studies’ refers to the study of different populations. Of the 35 included studies, 15 reported renal function of patients with CKD stage 3 and/or stage 4. Of these, 9 reported renal function of a single population and 6 reported results for two CKD subgroups or dose-dependent subgroups. CKD, chronic kidney disease; ROM, ratio of means.
Figure 6
Figure 6
Relative risk (RR) of cardiovascular disease during trials of lipid-modifying drugs versus comparator (boxes) and pooled estimates across trials (diamonds) calculated by the random-effects DerSimonian and Laird method, split by CKD stage. GREACEa, atorvastatin versus usual care for the group with metabolic syndrome; GREACEb, atorvastatin versus usual care for the group without metabolic syndrome. CKD, chronic kidney disease.
Figure 7
Figure 7
Relative risk (RR) of all-cause mortality during trials of lipid-modifying drugs versus comparator (boxes) and pooled estimates across trials (diamonds) calculated by the random-effects DerSimonian and Laird method, split by CKD stage. GREACEa, atorvastatin versus usual care for the group with metabolic syndrome; GREACEb, atorvastatin versus usual care for the group without metabolic syndrome. CKD, chronic kidney disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Detecting Variants in the NBN Gene While Testing for Hereditary Breast Cancer: What to Do Next?
    Zuntini R, Bonora E, Pradella LM, Amato LB, Vidone M, De Fanti S, Catucci I, Cortesi L, Medici V, Ferrari S, Gasparre G, Peterlongo P, Sazzini M, Turchetti D. Zuntini R, et al. Int J Mol Sci. 2021 May 29;22(11):5832. doi: 10.3390/ijms22115832. Int J Mol Sci. 2021. PMID: 34072463 Free PMC article. Review.
  • Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline.
    Gorski M, Jung B, Li Y, Matias-Garcia PR, Wuttke M, Coassin S, Thio CHL, Kleber ME, Winkler TW, Wanner V, Chai JF, Chu AY, Cocca M, Feitosa MF, Ghasemi S, Hoppmann A, Horn K, Li M, Nutile T, Scholz M, Sieber KB, Teumer A, Tin A, Wang J, Tayo BO, Ahluwalia TS, Almgren P, Bakker SJL, Banas B, Bansal N, Biggs ML, Boerwinkle E, Bottinger EP, Brenner H, Carroll RJ, Chalmers J, Chee ML, Chee ML, Cheng CY, Coresh J, de Borst MH, Degenhardt F, Eckardt KU, Endlich K, Franke A, Freitag-Wolf S, Gampawar P, Gansevoort RT, Ghanbari M, Gieger C, Hamet P, Ho K, Hofer E, Holleczek B, Xian Foo VH, Hutri-Kähönen N, Hwang SJ, Ikram MA, Josyula NS, Kähönen M, Khor CC, Koenig W, Kramer H, Krämer BK, Kühnel B, Lange LA, Lehtimäki T, Lieb W; Lifelines Cohort Study; Regeneron Genetics Center; Loos RJF, Lukas MA, Lyytikäinen LP, Meisinger C, Meitinger T, Melander O, Milaneschi Y, Mishra PP, Mononen N, Mychaleckyj JC, Nadkarni GN, Nauck M, Nikus K, Ning B, Nolte IM, O'Donoghue ML, Orho-Melander M, Pendergrass SA, Penninx BWJH, Preuss MH, Psaty BM, Raffield LM, Raitakari OT, Rettig R, Rheinberger M, Rice KM, Rosenkranz AR, Rossing P, Rotter JI, Sabanayagam C, Schmidt H, Schmidt R, Schöttker B, Schulz CA, Se… See abstract for full author list ➔ Gorski M, et al. Kidney Int. 2021 Apr;99(4):926-939. doi: 10.1016/j.kint.2020.09.030. Epub 2020 Oct 31. Kidney Int. 2021. PMID: 33137338 Free PMC article.
  • Associations Between Changes in Plasma Renin Activity and Aldosterone Concentrations and Changes in Kidney Function After Treatment for Primary Aldosteronism.
    Kobayashi Y, Haze T, Yano Y, Tamura K, Kurihara I, Ichijo T, Yoneda T, Katabami T, Tsuiki M, Wada N, Ogawa Y, Kawashima J, Sone M, Inagaki N, Yamada T, Okamoto R, Fujita M, Kamemura K, Yamamoto K, Izawa S, Tanabe A, Naruse M; JPAS/JRAS Study Group. Kobayashi Y, et al. Kidney Int Rep. 2020 Jun 20;5(8):1291-1297. doi: 10.1016/j.ekir.2020.06.012. eCollection 2020 Aug. Kidney Int Rep. 2020. PMID: 32775828 Free PMC article.
  • Longitudinal Lipid Trajectories and Progression of CKD in Children.
    Querfeld U, Kirchner M, Mencarelli F, Azukaitis K, Bayazit A, Duzova A, Doyon A, Canpolat N, Bulut IK, Obrycki L, Bacchetta J, Shroff R, Paripovic D, Candan C, Harambat J, Yilmaz A, Alpay H, Oh J, Erdogan H, Schmitt CP, Melk A, Schaefer F. Querfeld U, et al. Kidney Int Rep. 2025 Feb 17;10(5):1393-1403. doi: 10.1016/j.ekir.2025.02.007. eCollection 2025 May. Kidney Int Rep. 2025. PMID: 40485719 Free PMC article.
  • Association of lipid profiles with severity and outcome of acute ischemic stroke in patients with and without chronic kidney disease.
    Zhang A, Deng W, Zhang B, Ren M, Tian L, Ge J, Bai J, Hu H, Cui L. Zhang A, et al. Neurol Sci. 2021 Jun;42(6):2371-2378. doi: 10.1007/s10072-020-04791-x. Epub 2020 Oct 13. Neurol Sci. 2021. PMID: 33048272 Free PMC article.
See all "Cited by" articles

References

    1. Hill NR, Fatoba ST, Oke JL, et al. . Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0158765 10.1371/journal.pone.0158765 - DOI - PMC - PubMed
    1. Go AS, Chertow GM, Fan D, et al. . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–305. 10.1056/NEJMoa041031 - DOI - PubMed
    1. National Institute for Health and Care Excellence Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care (CG182. London: National Clinical Guideline Centre, 2014. - PubMed
    1. Levey AS, Eckardt K-U, Tsukamoto Y, et al. . Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 2005;67:2089–100. 10.1111/j.1523-1755.2005.00365.x - DOI - PubMed
    1. Levin A, Stevens PE. Summary of KDIGO 2012 CKD guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 2014;85:49–61. 10.1038/ki.2013.444 - DOI - PubMed

Publication types

MeSH terms